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Objective: To examine use of complementary and alternative medicine (CAM) among individuals with
radiographic-conﬁrmed osteoarthritis (OA) of the knee.
Methods: We included 2679 participants of the Osteoarthritis Initiative with radiographic tibiofemoral
knee OA in at least one knee at baseline. Trained interviewers asked a series of speciﬁc questions relating
to current OA treatments including CAM therapies (seven categories e alternative medical systems,
mind-body interventions, manipulation and body-based methods, energy therapies, and three types of
biologically based therapies) and conventional medications. Participants were classiﬁed as: (1) conven-
tional medication users only, (2) CAM users only; (3) users of both; and (4) users of neither. Polytomous
logistic regression identiﬁed correlates of treatment approaches including sociodemographics and
clinical/functional correlates.
Results: CAM use was prevalent (47%), with 24% reporting use of both CAM and conventional medication
approaches. Multi-joint OA was correlated with all treatments (adjusted odds ratios (aOR) conventional
medications only: 1.62; CAM only: 1.37 and both: 2.16). X-ray evidence of severe narrowing (OARSI grade
3) was associated with use of glucosamine/chondroitin (aOR: 2.20) and use of both (aOR: 1.98). The
Western Ontario and McMaster Universities (WOMAC)-Pain Score was correlated with conventional
medication use, either alone (aOR: 1.28) or in combination with CAM (aOR: 1.41 per one standard
deviation change). Knee Outcomes in Osteoarthritis Survey (KOOS)-Quality of Life (QOL) and Short Form
(SF)-12 Physical Scale scores were inversely related to all treatments.
Conclusion: CAM is commonly used to treat joint and arthritis pain among persons with knee OA. The
extent to which these treatments are effective in managing symptoms and slowing disease progression
remains to be proven.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
By the year 2020, 59.4million persons in the United Stateswill be
affected by arthritis1. Osteoarthritis of the knee (OAK) is the leading
cause of disability in the United States2, and population-based
projections of the probable need for total knee arthroplasty indi-
cate steady increases in all age groups3. Patients suffering from OAK
seek effective treatments (e.g., physical or occupational therapy,ate L. Lapane, Department of
onwealth University, 800 East
l: 1-804-628-2506.
s Research Society International. Pweight loss, pharmacologic approaches) for pain relief, as well as
minimizing functional limitations of symptoms and to attempt to
slowdisease progression4. In additional to conventionalmedications,
complementary and alternative medicine (CAM) (including herbal
remedies, acupuncture, supplements)5 increasingly are used. Indeed,
arthritis is among the top six conditions for which CAM is used6.
Previous reports have demonstrated that CAM use differs by age
group7, gender8, race/ethnicity9,10, educational attainment11, annual
household income, employment status8, and health insurance status.
However, the extent to which the existing literature on CAM use
(based on self-report) extends to a population with radiographic
conﬁrmation of OAK is unknown. Also, standardized measures of
performance, function, quality of life and pain are frequently absent
from studies of CAMamong personswithOAK. Lastly,most studies ofublished by Elsevier Ltd. All rights reserved.
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entiated the use a combination of CAM and conventional medical
approaches. Thus, we examined the use of CAM and conventional
medication approaches in a large number of participants of the
Osteoarthritis Initiative (OAI).
Subjects and methods
The Institutional Review Boards of Virginia Commonwealth
University and theMemorial Hospital of Rhode Island approved the
study protocol.
Data source
We used publicly available data from the OAI (http://www.oai.
ucsf.edu/) (#AllClinical00, V0.2.2). The OAI began enrolling people
aged 45 through 79 years in 2004 and followed them annually for
the development or progression of OAK. The clinical sites involved
were Baltimore, MD; Columbus, OH; Pittsburgh, PA; and Pawtucket,
RI. Participants were ineligible if any of the following were present:
(1) rheumatoid arthritis or inﬂammatory arthritis; (2) severe joint
space narrowing in both knees or unilateral total knee arthroplasty
and severe joint space narrowing in the contralateral knee;
(3) inability to undergo 3.0 T magnetic resonance imaging (MRI)
examination of the knee; (4) a positive pregnancy test; (5) inability
to provide a blood sample; (6) use of ambulatory aids aside from the
use of a single straight cane for 50% of ambulation time or more;
(7) co-morbid conditions that might interfere with ability to
participate in a study with a 4-year follow-up time; or (8) unlike-
lihood to reside in the clinic area for at least 3 years12. The overall
study included 4796 participants.
Study sample
For the current study, we included individuals with radiographic
tibiofemoral OAK in at least one knee at baseline (N¼ 2679).
Readers from each clinical site were trained to assess baseline ﬁxed
ﬂexion knee X-rays for osteophytes and joint space narrowing.
Training consisted of a didactic and interactive components using
a web-based system that included scoring a training set of knee
X-rays. Radiographic tibiofemoral OAK was deﬁned as the presence
of an Osteoarthritis Research Society International (OARSI) atlas
osteophyte grade 1e3 (equivalent to Kellgren and Lawrence
grade 2) on a ﬁxed ﬂexion radiograph based on the readings
results provided by the individual clinical sites13.
Exposure categories
We decided to create a four level variable to simultaneously
categorize participants according to their CAM and conventional
medication use. Previously, reports have focused on correlates of
CAM use, without regarding use of conventional medications. Yet,
we speculated that use of both strategieswere common and that the
factors associated with monotherapy (CAM or conventional), may
be different to those associated with use of combined therapies.
Participants were asked “During the past 30 days, have you used
any of the following medications for joint pain or OA on most days?
By most days, we mean more than half the days of the month.”
Participants were asked separate questions for: acetaminophen,
over-the-counter non-steroidal anti-inﬂammatory agents (NSAIDs),
prescription NSAIDs, prescription cyclooxygenase-2 (COX-2)
inhibitors, doxycycline and prescription “strong pain” medications
such as opioids. Interviewers asked “During the past 6 months, did
you use the following health supplements for joint pain or
arthritis?” with separate questions for chondroitin sulfate andglucosamine. A series of questions speciﬁcally asked about the use
of CAM approaches for arthritis or joint pain during the past year, as
well as how frequently practitioners were seen. Responses from
these questions were used to classify participants as: conventional
medication users only, CAM users only, both CAM and conventional
users, and users of neither.
Medications often used in themanagement of OAK includeduse of
acetaminophen, over-the-counter NSAIDs (e.g., aspirin, ibuprofen,
naproxen), NSAIDs requiring a prescription (e.g., ibuprofen at higher
doses, diclofenac, naproxen), COX-2 selective inhibitors (e.g., valde-
coxib, rofecoxib, celecoxib), hyaluronic acid, steroids/injected corti-
costeroids, and calcitonin. Todifferentiate fromCAM,we labeled these
treatments as conventionalmedications.We considered CAM5 as any
indication of use of: (1) alternative medical systems (acupuncture,
acupressure, homeopathy and others); (2) mind-body interventions
(yoga/Tai Chi/Chi Gong/pilates, spiritual activities, relaxation therapy,
meditation, deep breathing or visualization); (3) manipulation and
body-based methods (Chiropractic and massage); (4) energy thera-
pies (copper bracelets or magnets); (5) topical biologically based
therapies including rubs, lotions, liniments, creams or oils (tiger balm,
horse liniment), capsaicin; (6) biologically based diet; or (7) biologi-
cally based supplements (e.g., herbals, glucosamine, chondroitin,
vitamins/minerals, methylsulfonylmethane (MSM), S-adenosylme-
thionine (SAME)). Because glucosamine and chondroitin are not
considered as CAM in some countries, we also separated the use of
glucosamine and chondroitin from other CAM treatments.
Potential correlates
Based on a non-systematic literature review, we considered
several conceptual domains as potential correlates of treatment
approach for OA: sociodemographic indicators, body mass index
(BMI), overall measures of mental and physical wellbeing, and clin-
ical indicesofOAK.Wehypothesized thatCAMusewouldbedifferent
by age group7, gender8, race/ethnicity9,10, educational attainment11,
annual household income, employment status8, and health insur-
ance status. Gender, age, and race/ethnicity were based on self-
report. Participants were considered employed if they reported
currently working or planning to return to work within 6 months.
Health insurance coverage status was identiﬁed as “currently having
private health insurance, prepaid plans, Preferred Provider Organi-
zations or any government-sponsored plans”. Participants were also
classiﬁed as having insurance that covered prescriptionmedications.
In the general population, obesity is inversely related to use of
CAM14. Trained examiners measured height (mm) twice during
held inspiration. BMI was calculated from measured height and
weight [weight (kg)/height (m2)]. Participants with a BMI between
25 and less than 30 were deﬁned as overweight, 30 to less than 35
as obese, and 35 and over as morbidly obese15.
The Medical Outcomes Study Short Form 12 (SF-12) was used to
assess general physical health status. The SF-12 consists of 12 ques-
tions covering eight health domains (physical functioning, social
functioning, role-physical, role-emotional, mental health, energy/
vitality, pain, and general health perception)16. The questions were
combined, scored, and weighted to create the Physical Health Scale
and Mental Health Score (ranging from 0 (lowest level of health) to
100 (highest level)). The Center for Epidemiologic Studies Depression
(CES-D) 20 item Scale17 was used to evaluate the depression status
and participants with scores above 16 were considered to have
clinical levels of depression.
We also considered indicators of symptoms and severity of OAK
including pain, quality of life, performance and function, and disease
severity. For the measure of pain, we used the Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index (Likert Version
3.1). Although the WOMAC measures three separate dimensions18,19,
Table I
Characteristics of CAM use by category* (N¼ 1259)
Category N % Of all CAM
users (95% CIy)
Alternative medical systems 31 2.5
Acupuncture 17 1.4
Acupressure 6 0.5
Chelation therapy 0 0
Folk medicine 0 0
Homeopathy 6 0.5
Ayurveda/biofeedback/energy
healing/hypnosis/naturopathy
10 0.8
Mind-body interventions 285 22.6
Yoga/Tai Chi/Chi Gong/pilates 153 12.2
Relaxation therapy, meditation,
deep breathing or visualization
94 7.5
Spiritual activities 104 8.3
Manipulation and body-based methods 140 11.1
Chiropractic 115 9.1
Massage 48 3.8
Energy therapies (copper bracelets or magnets) 95 7.6
Biologically based therapies: topical agent 358 28.4
Rubs, lotions, liniments, creams
or oils (tiger balm/horse liniment)
352 28.0
Capsaicin 45 3.6
Biologically based therapies: diet 31 2.5
Biologically based therapies: supplements 856 68.0
Herbs 43 3.4
Vitamins/minerals (nearly every day) 168 13.3
Glucosamine (nearly every day) 740 58.8
MSM 153 12.2
SAME 13 1.0
Chondroitin (nearly every day) 675 53.6
* As deﬁned by the National Center for Complementary and Alternative Medicine.
y CIs were calculated based on asymptotic Gaussian approximation.
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contains ﬁve Likert responses, ranging from ‘0¼ none’ to
‘4¼ extreme’, which were summed to produce the pain subscale
scores (maximum score 20 indicating the worst pain). We also used
the Knee Outcomes in Osteoarthritis Survey (KOOS) as an indicator of
knee related quality of life. The KOOS assesses knee symptoms and
function during more demanding activities (e.g., during sport and
recreation)20. The KOOS quality of life scale was estimated by
summing the responses to four items with ﬁve Likert responses,
ranging from 0 to 4 and computing a normalized score ranging from
0 to 100 (100 indicating no symptoms and 0 indicating extreme
symptoms). For the WOMAC and KOOS measures, we evaluated the
right and left knees separately and used the knee with worse
measures. Formeasures of performance and functionwe used a 20-m
walk to measure walking ability and endurance21. The average dura-
tion (seconds) of completing the 20-mwalk was calculated based on
two trials. The chair stand test was used as a direct assessment of
integrated physical performance involving leg strength and knee
function22. The chair stand time was deﬁned as the time duration
(seconds) of standing up and sitting down ﬁve times as quickly as
possible. Disease severity was measured in two ways. First, we clas-
siﬁed participants by the X-ray joint space narrowing as determined
by the OARSI atlas osteophyte grade 1e3 (equivalent to Kellgren and
Lawrence grade 2) on a ﬁxed ﬂexion radiograph13. The worst
measure of two knees was used. Second, to capture multiple-joint OA
symptoms we considered: low back pain in previous 30 days, OA in
hand, hip symptoms, hip replacement and knee injury history
(including knee injury and knee surgery) as reported at baseline.
Statistical analyses
We compared the sociodemographic and clinical characteristics
of users in each group (conventional medication use only, CAM use
only, use of both CAM and conventional medications) to the referent
group e non-users of CAM/conventional medications by conducting
chi-square tests for categorical data and t-tests for continuous vari-
ables. Rather than overall chi-square tests, each groupwas compared
to the referent group. Next, we used polytomous logistic regression
modeling to identify correlates of treatment approaches by
comparing the odds of using conventional medications only, using
CAM approaches only, using both CAM and conventional approaches
with non-users. In our polytomous logistic regression model, the
outcome variable represented four categories. The models for each
(three models for four categories) are simultaneously ﬁt by using
maximum likelihood to estimate adjusted odds ratios (aOR) for each
group comparedwith a common reference group23. Beforemodeling
we evaluated (and ruled out) the potential for multicollinearity
amongst the potential correlate variables under study by checking
correlations between the covariates. When two variables were
correlated (e.g., education and income), we elected to include only
one of the variables (e.g., education) in our ﬁnal model. During the
modeling process, the standard errors for the variables were also
evaluated for indications of multicollinearity. If inﬂated standard
errorswere apparent,we droppedoneof the collinear variables from
the model. We used an iterative, but not computer driven approach
to develop the ﬁnal model of correlates. To provide more clinically
meaningful results for the SF-12 Physical Scale, WOMAC-Pain, and
KOOS-Quality of Life (QOL),we provide odds ratios for a one standard
deviation change in each variable. To further differentiate correlates
amongst the different CAM approaches, we created a separate pol-
ytomous logistic regression model with the following outcome
variable: use of glucosamine/chondroitin only, use of other CAM
approaches only, using both CAM and conventional approaches and
non-users. The same modeling strategies described above were
applied to this model.Results
The majority of the sample was white, well educated, and
covered by health insurance. Use of CAM was common (47%, 95%
conﬁdence interval (CI): 45e49%). Sixteen percent (95% CI: 15e18%)
used conventional medications only, 23% (95% CI: 21e25%) used
CAM only, and 24% (95% CI: 22e26%) used both CAM and conven-
tional medications. Table I shows the speciﬁc types of CAM used.
Forty-seven percent reported use of at least one CAM method. Of
these, 32% (95% CI: 29e35%) reported use of at least two CAM
approaches. The use of biologically based supplements was the
most often used method (68%), followed by biologically based
topical agents (28%), and mind-body interventions (23%). Of CAM
users, 54% used chondroitin, 59% used glucosamine, 12% usedMSM,
and 13% used vitamins/minerals nearly every day. Almost 8% re-
ported use of energy therapies. Use ofmind-body interventionswas
common (23%),with 12%of CAMusers reporting use ofmethods like
yoga or Tai Chi, w8% reporting techniques such as meditation or
visualization, and 8% reporting spiritual activities. The distributions
were similar regardless of conventional medication use except for
spiritual activities which were more common among users of CAM
and conventional medications (26%) than CAM only users (19%).
Table II shows the characteristics of the participants by treatment
approaches: conventional only, CAM only, both, or neither. The age
distribution was similar across categories of CAM and conventional
medication use, while differences in the gender distribution were
present. Women were more likely to use any treatment
(60% conventional medication only users, 61% CAM (only users, 67%
both and 51% neither). The distribution of race/ethnicity was similar
among those reporting use of both conventional and CAM
approaches to those reporting use of neither approach. Those
Table II
Characteristics of participants with radiographic-conﬁrmed knee OA by
conventional and CAM treatment approaches (N¼ 2679)
Conventional
medications
only (N¼ 440)
CAM use
only
(N¼ 618)
Both
(N¼ 641)
Neither
(N¼ 980)
Percentage*
Women 59.6 60.5 66.6 51.0
Age (years) 65 41.4 45.2 44.3 42.4
Race/ethnicity
White 68.9 81.2 77.0 79.3
Black/African American 28.6 13.6 19.8 17.5
Latino 1.4 1.1 1.9 1.3
Other 1.1 4.1 1.3 1.9
Education
>College 45.0 63.0 52.1 57.6
Some college 28.9 23.0 29.8 24.4
High school 26.2 14.0 18.1 18.0
Income ($)
>100,000 17.7 21.6 22.7 22.3
50ke100k 32.4 38.4 31.8 38.3
25ke50k 27.8 28.0 28.7 25.8
25,000 22.1 12.0 16.8 13.6
Married/partnered 61.5 70.0 63.5 66.4
Working (for pay) 54.2 61.3 55.5 60.2
Health insurance 92.9 97.7 97.2 97.6
Insurance covers
prescriptions
84.7 86.0 87.0 88.6
BMI (kg/m2)
35 (Morbidly obese) 19.2 8.3 17.3 12.0
30 to <35 (Obese) 34.0 30.0 28.9 29.1
25 to <30 (Overweight) 36.5 40.4 35.3 41.5
<25 (Normal) 10.3 21.4 18.4 17.4
CES-D> 16 (depressed) 15.0 5.8 12.0 7.1
Mean
(standard
deviation)
SF-12 mental summary 52.7 (9.7) 54.7 (7.3) 53.8 (8.9) 53.9 (7.5)
SF-12 physical summary 44.3 (10.1) 48.8 (8.8) 44.1 (9.6) 50.7 (8.3)
* May not total 100% due to rounding.
Table III
Clinical characteristics of participants with radiographic-conﬁrmed knee OA by conventi
Conventional medica
only (N¼ 440)
Symptoms Mean (standard devia
WOMAC-Pain 5.3 (4.4)
KOOS-QOL 57.0 (23.5)
Function and performance
Chair stands (seconds) 13.0 (4.5)
20-m Walk (seconds) 16.8 (3.5)
Joint space narrowing: X-ray evidence of knee severity Percentage*
OARSI grade 0 (normal) 28.2
OARSI grade 1e2 (narrowed) 50.2
OARSI grade 3 (severe) 21.6
Multi-joint OA
Any back pain (30 days) 63.4
Hand OA 23.2
Hip symptoms (12 months) 28.3
Total hip replacement 3.0
History
History of knee injury 46.4
History of knee surgery 32.3
Mean (standard devia
Weight at age 25 (kg) 68.8 (13.8)
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be Black/African American (29%), whereas users reporting only CAM
use were less likely to report being Black/African American (14%)
relative to non-users of either group (18%).
Relative to non-users of CAM and conventional medications,
those reporting only the use of conventional medications had less
education, and were less likely to report being employed. Most
reported health insurance coverage, with no differences in the
percent with health insurance providing prescription medication
coverage by treatment approach. The distribution of BMI differed
between the conventional medication only group and those
reporting use of CAM and conventional medications compared to
non-users of either approach. Physical summary scores were less in
each treatment group relative to the group using neither approach.
Table III shows the clinical and functional characteristics of the
participants stratiﬁed by treatment group. Compared to participants
not using anyCAMtherapies or conventionalmedications, eachof the
other treatment groups had higher pain scores and lower quality of
life indices. While CAM only users had functional and performance
indicators similar to the no treatment group, users of conventional
medications and users of CAM and conventional medications took
longer on the functional tests. Correspondingly, all treatment groups
had worsening X-ray evidence of joint space narrowing relative to
participants who reported no CAM or conventional medication use.
Users of both CAM and conventional medications (29%), CAM only
users (23%), conventionalmedication users (22%)weremore likely to
have severe joint space narrowing relative to non-users of CAM and
conventional medicines (14%). Although overall total hip replace-
ment was infrequent (<3%), its occurrence was greater in the
conventionalmedicationusers only and in the CAMand conventional
medicationuse group relative to thenon-users.HandOAwas twice as
prevalent in each of the exposure groups relative to the non-users.
Hip symptoms in the past 12 months were most often reported in
users of CAM and conventional medications (w36%) followed by
conventional medication users only (28%), CAM only users (25%),
and non-users (15%). While history of knee injury was only more
common in CAM only users relative to non-users (51% vs 45%),
history of knee surgery was more prevalent among conventional
medication users (32%) and CAM and conventional medication
users (33%) relative to non-users (26%).onal and CAM treatment approaches (N¼ 2679)
tions CAM use only
(N¼ 618)
Both (N¼ 641) Neither (N¼ 980)
tion)
3.5 (3.4) 5.8 (4.2) 2.8 (3.3)
64.0 (20.7) 52.0 (22.0) 70.9 (21.6)
11.2 (3.6) 12.4 (4.2) 11.1 (3.3)
15.6 (2.9) 16.5 (3.6) 15.4 (2.5)
29.1 24.5 35.3
48.2 46.8 50.6
22.7 28.7 14.1
55.2 69.0 51.1
18.7 26.8 10.5
25.0 36.1 15.0
1.5 3.0 1.0
51.0 49.8 44.7
30.7 32.9 25.5
tion)
66.8 (13.6) 67.3 (13.9) 68.7 (14.0)
Table V
Sociodemographic and clinical correlates* of glucosamine/chondroitin use, other
CAM use among participants with radiographic-conﬁrmed knee OA
Glucosamine/
chondroitin use
only (N¼ 373)
Other CAM use
only (N¼ 245)
aOR (95% CI)
Age 65 years 1.26 (0.95e1.67) 1.10 (0.79e1.53)
Women 1.66 (1.26e2.18) 2.25 (1.61e3.14)
Race/ethnicity
Black 0.39 (0.24e0.65) 1.09 (0.72e1.63)
Latino 0.47 (0.10e2.21) 0.82 (0.18e3.86)
Other 1.74 (0.80e3.78) 2.52 (1.12e5.67)
Non-Hispanic White 1.0 1.0
Education
College graduate 2.18 (1.42e3.34) 1.19 (0.78e1.82)
Some college 1.37 (0.85e2.22) 1.21 (0.77e1.90)
High school or less 1.0 1.0
BMI
Morbid obesity 0.56 (0.32e0.96) 0.73 (0.40e1.35)
Obesity 0.81 (0.55e1.17) 1.19 (0.75e1.89)
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participants with radiographic-conﬁrmed knee OA. Women were
more likely than men to use any method (CAM or conventional
medications). Black participants were less likely than non-Hispanic
Whites to use CAM therapies either alone (aOR: 0.71; 95% CI:
0.51e1.00) or in combination (aOR: 0.54; 95% CI: 0.38e0.76). Rela-
tive to participants with a high school education or less, those who
graduated from college were more likely to use strategies that
included CAM (aOR CAM only: 1.64; aOR Both: 1.48). Those with
higher scores on the SF-12 (physical summary) and the KOOS-QOL
were less likely to receive any treatments. Total hip replacement
more than tripled the likelihood of use of conventionalmedications,
either with or without CAM. X-ray evidence of severe narrowing
(OARSI grade 3)was associatedwith strategies using CAM (aORCAM
only: 1.63; 95% CI: 1.16e2.29; aOR Both: 1.98; 95% CI: 1.39e2.82).
The analyses in Table V further reﬁne the classiﬁcation of CAM
into: (1) glucosamine or chondroitin users (with most participants
reporting use of both therapies); and (2) other CAM therapies.
When classiﬁed this way, women are twice as likely to report use ofTable IV
Sociodemographic and clinical correlates* of treatment use among participants with
radiographic-conﬁrmed knee OA (N¼ 2679)
Conventional
medications
only (N¼ 440)
CAM use only
(N¼ 618)
Both (N¼ 641)
aOR (95% CI)
Age 65 years 1.01 (0.77e1.33) 1.18 (0.93e1.49) 1.17 (0.91e1.50)
Women 1.37 (1.04e1.79) 1.86 (1.47e2.34) 2.21 (1.72e2.84)
Race/ethnicity
Black 0.90 (0.64e1.27) 0.71 (0.51e1.00) 0.54 (0.38e0.76)
Latino 0.77 (0.23e2.61) 0.61 (0.19e1.98) 1.47 (0.57e3.76)
Other 0.65 (0.23e1.85) 2.00 (1.03e3.91) 0.43 (0.16e1.18)
Non-Hispanic
White
1.0 1.0 1.0
Education
College
graduate
0.91 (0.65e1.29) 1.64 (1.19e2.28) 1.48 (1.06e2.07)
Some college 0.99 (0.69e1.42) 1.26 (0.88e1.80) 1.35 (0.94e1.93)
High school or
less
1.0 1.0 1.0
BMI
Morbid obesity 1.53 (0.93e2.53) 0.61 (0.39e0.94) 0.85 (0.55e1.30)
Obesity 1.41 (0.91e2.17) 0.91 (0.66e1.26) 0.75 (0.52e1.06)
Overweight 1.33 (0.88e2.02) 0.88 (0.65e1.18) 0.71 (0.51e0.99)
Normal weight 1.0 1.0 1.0
Depression 1.31 (0.87e1.99) 0.80 (0.51e1.24) 1.09 (0.72e1.63)
SF-12 Physical
Scaley
0.74 (0.63e0.87) 0.88 (0.76e1.03) 0.83 (0.71e0.96)
WOMAC-Painy 1.28 (1.05e1.55) 1.01 (0.84e1.22) 1.41 (1.18e1.68)
KOOS-QOLy 0.75 (0.62e0.91) 0.69 (0.58e0.82) 0.54 (0.45e0.64)
History of knee
injury/surgery
1.13 (0.86e1.47) 1.28 (1.02e1.61) 1.01 (0.79e1.29)
Hip replacement 3.86 (1.54e9.67) 1.41 (0.51e3.93) 4.49 (1.84e10.96)
Multi-joint OA 1.62 (1.22e2.14) 1.37 (1.09e1.72) 2.16 (1.65e2.81)
Chair stands
(seconds)
1.03 (0.99e1.07) 0.97 (0.94e1.01) 1.00 (0.96e1.03)
OARSIz grade
Grade 3 (severe) 1.38 (0.94e2.03) 1.63 (1.16e2.29) 1.98 (1.39e2.82)
Grade 1e2
(narrowed)
1.06 (0.79e1.41) 1.13 (0.88e1.44) 1.19 (0.91e1.57)
Grade 0 (normal) 1.0 1.0 1.0
* Reference group for the outcome includes patients who did not report use of
CAM or conventional medications for OA treatment. Odds ratios shown are adjusted
for all variables shown on the table.
y Odds ratios are per one standard deviation change in SF-12 Physical Scale
(standard deviation¼ 9.5), WOMAC-Pain scale (standard deviation¼ 4.0), and
KOOS-QOL scale (standard deviation¼ 23.1).
z X-ray evidence of joint space narrowing.
Overweight 0.78 (0.56e1.10) 1.12 (0.72e1.75)
Normal weight 1.0 1.0
Depression 0.50 (0.26e0.94) 1.16 (0.68e1.95)
SF-12 Physical Scaley 0.98 (0.81e1.19) 0.78 (0.64e0.96)
WOMAC-Painy 0.92 (0.73e1.15) 1.14 (0.90e1.45)
KOOS-QOLy 0.63 (0.51e0.76) 0.80 (0.63e1.01)
History of knee
injury/surgery
1.35 (1.02e1.78) 1.16 (0.85e1.59)
Hip replacement 1.72 (0.55e5.36) 1.00 (0.21e4.75)
Multi-joint OA 1.35 (1.03e1.77) 1.41 (1.02e1.95)
Chair stands (seconds) 0.96 (0.91e1.00) 0.99 (0.94e1.04)
OARSIz grade
Grade 3 (severe) 2.20 (1.48e3.26) 1.02 (0.63e1.64)
Grade 1e2
(narrowed)
1.33 (0.98e1.81) 0.90 (0.65e1.26)
Grade 0 (normal) 1.0 1.0
* Reference group for the outcome includes patients who did not report use of
CAM or conventional medications for OA treatment. Odds ratios shown are adjusted
for all variables shown on the table. Results for conventional medications only and
users of both CAM and conventional medications are not shown as the odds ratios
are virtually the same as those shown in Table IV.
y Odds ratios are per one standard deviation change in SF-12 Physical Scale
(standard deviation¼ 9.5), WOMAC-Pain scale (standard deviation¼ 4.0), and
KOOS-QOL scale (standard deviation¼ 23.1).
z X-ray evidence of joint space narrowing.other CAM therapies relative to men (aOR: 2.25; 95% CI: 1.61e3.14).
While Black participants were nomore or less likely to report use of
other CAM treatments, they were much less likely to report use of
glucosamine or chondroitin (aOR: 0.39; 95% CI: 0.24e0.65). Further,
thosewith at least a college educationwere twice as likely to report
glucosamine/chondroitin use relative to those with a high school
education or less, but education did not correlate with use of other
CAM therapies. Severity of disease also did not correlate with other
CAM use, but was associated with a greater likelihood of glucos-
amine/chondroitin use.
Discussion
We found use of CAM approaches to be common. Forty-seven
percent of participants of the OAI with radiographic-conﬁrmed
OAK reported use of at least one CAM approach, which is lower
than previous reports9,24,25, but similar as other studies with speciﬁc
focus onOAK26. Estimates of CAMuse from other studies varywidely
(34e90%25) owing to differences in the operational expression of
CAMuse (e.g., including prayer), differences in the time referent (e.g.,
ever use, use in past month), population included (e.g., all conditions
vs OAK), as well as geographic differences.
K.L. Lapane et al. / Osteoarthritis and Cartilage 20 (2012) 22e28 27This study documents that persons with OAK commonly use
multiple treatment approaches. Indeed, 24% reported use of at least
one CAM approach in addition to conventional pharmacologic
medicines and 32% of CAM users reported recent use of multiple
CAM approaches. The most common CAM approach was use of
biologically based supplements. Despite widespread use, patients
may not disclose their use of CAM to physicians27 and even if dis-
cussed, CAM use is not frequently documented in the medical
record28. The extent towhich herbal remedies and supplementsmay
interact with conventional medications is non-trivial29. Unless CAM
use is integrated into electronic medical records, averting such
interactions is unlikely. Given the extent of dual use of approaches,
physicians should be encouraged to ask patients about CAM use and
document use. Electronic medical record systems allowing elec-
tronic prescribing should have the ability to check for such drug-
herb or drug-supplement interactions at the point of prescribing,
as this may be the only place in the pharmacy-care process where
such interactions can be detected.
We found that participants with greater physical wellbeing as
measured with standardized tools including the KOOS-QOL and SF-
12 had reduced use of any treatment. Indication of clinical
depression was not associated with OA treatment. Although there
are many accepted CAM approaches to treatment of depression30,
increased use of CAM among persons with depression was not
observed in previous research11 or in the current study. Indeed,
persons with depression were half as likely to report glucosamine/
chondroitin use. Our ﬁndings contradict previous research linking
depression among persons with OA to greater health care utiliza-
tion (e.g., greater contacts with primary care providers, orthopedic
doctors, and CAM practitioners)31. These important differences
between CAM and non-CAM users in co-morbid conditions, phys-
ical functioning and severity of illness will likely lead to con-
founding by indication when evaluating the beneﬁts of CAM use
using non-experimental paradigms. As such, novel analytic
approaches to address such confounding in comparative effec-
tiveness research of CAM must be employed.
Our study conﬁrmed several important associations between
treatment approaches and sociodemographic factors. We conﬁrmed
previous reports between gender and treatment options32, with
greater associations noted with CAM use (either alone or in
conjunctionwith conventionalmedications). As others have shown11,
persons with more education were more likely to select treatment
options including CAM. In our study, more education was associated
with increased reported use of glucosamine/chondroitin. Relative to
non-Hispanic Whites, Blacks were less likely to use CAM treatments
(either alone or in conjunction with conventional medications) rela-
tive to no treatments. The lack of CAM use by Blacks was owing to
decreased use of glucosamine/chondroitin. This ﬁnding contradicts
previous reports showing that Black persons with OA are more likely
to use CAM and conventional medications9. The extent to which our
ﬁndings are subject to information bias, as others suggest27 remains
unknown. Persons with greater levels of obesity were more likely
to reportuseof conventionalmedications than thosewithBMI< 25 k/
m2. Previous research14 noted that adults with higher BMIs were no
more likely touse eachof the individualCAMtherapyand less likely to
use supplements relative to normal weight adults. This is consistent
with the ﬁnding in our study that morbidly obese persons were
almost half as likely to report use of glucosamine/chondroitin.
Our ﬁndings must be considered with limitations in mind. The
data on treatments were obtained at the same time themeasures of
function and pain were collected. No questions were asked about
omega-3 or seal oil. This cross-sectional study precludes state-
ments of predictors of use and associations are confounded by
potential treatment effects. Recall bias of treatments among
persons with OAK has been documented33. Treatments were basedon a 30 day and 6 month recall so it is possible that participants did
not accurately report the use of treatments. These concerns may
have introduced misclassiﬁcation in assignment of participants to
the treatment approaches which would have diluted any observed
associations. The OAI data do not provide information regarding
whether or not CAM treatments and conventional medications
were actually covered by the participants’ health insurance. We
were unable to evaluate the impact of insurance coverage on use of
these treatments. As with other studies34, our ﬁndings are not
generalizable to all persons with OAK owing to selective partici-
pation in research. In particular, most of the people in our sample
were employed, had health insurance, and were well educated. The
sample also excluded persons with severe OAK.
Our study demonstrates that CAM use (with or without conven-
tional medication use) is common in persons with radiographic-
conﬁrmed OAK, and that frequently multiple CAM approaches are
used either alone or in conjunction with conventional medication
use. Our ﬁnding that use of treatments is associated with severity of
disease and pain indicators suggests that management of OAK may
not be optimal. Sociodemographic, as well as functional and clinical
factors related to pain and quality of life are correlated to choice of
treatment options. Physicians caring for persons with OAK should
understand their patients’ CAM practices, educate patients of the
latest understanding of the usefulness of CAM approaches, and
discuss the potential risks associated with CAM and conventional
treatments. While previous research has documented the potential
adverse effects of both conventional and CAM approaches, more
evidence is needed to demonstrate the effectiveness of these treat-
ment approaches either alone or in combination with other CAM
approaches35 or conventional medications36,37 as the costs of treat-
ment equal to costs of traditional medicine26. Our data demonstrate
the need for improved overall management, and potentially greater
access to total knee replacements if non-surgical approaches do not
sufﬁciently address the patients’ needs.
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